These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 30726549

  • 41. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
    Ladaique M, Dirani A, Ambresin A.
    Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
    [Abstract] [Full Text] [Related]

  • 45. UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice.
    Lee AY, Lee CS, Egan CA, Bailey C, Johnston RL, Natha S, Hamilton R, Khan R, Al-Husainy S, Brand C, Akerele T, Mckibbin M, Downey L, Tufail A.
    Br J Ophthalmol; 2017 Dec; 101(12):1683-1688. PubMed ID: 28478396
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H, Abrams P.
    Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY, Kwon KY, Byeon SH.
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
    Roller AB, Amaro MH.
    Arq Bras Oftalmol; 2009 Sep; 72(5):677-81. PubMed ID: 20027409
    [Abstract] [Full Text] [Related]

  • 56. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM, Simader C, Staurenghi G, Chong NV, Mitchell P, Jaffe GJ, Lu C, Katz TA, Schmidt-Erfurth U.
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [Abstract] [Full Text] [Related]

  • 57. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC, Nguyen V, Daien V, Arnold JJ, Morlet N, Barthelmes D.
    Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.
    Hopley C, Salkeld G, Mitchell P.
    Br J Ophthalmol; 2004 Aug; 88(8):982-7. PubMed ID: 15258009
    [Abstract] [Full Text] [Related]

  • 60. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG, Comparison of Age-related Macular Degeneration Treatments Trials Research Group.
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.